CN109476698B - 基于基因的炎性肠病诊断 - Google Patents

基于基因的炎性肠病诊断 Download PDF

Info

Publication number
CN109476698B
CN109476698B CN201780044934.7A CN201780044934A CN109476698B CN 109476698 B CN109476698 B CN 109476698B CN 201780044934 A CN201780044934 A CN 201780044934A CN 109476698 B CN109476698 B CN 109476698B
Authority
CN
China
Prior art keywords
various embodiments
ibd
gene
dna
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780044934.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109476698A (zh
Inventor
D·P·麦戈文
李大林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60326226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109476698(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority to CN202311263442.0A priority Critical patent/CN117286238A/zh
Publication of CN109476698A publication Critical patent/CN109476698A/zh
Application granted granted Critical
Publication of CN109476698B publication Critical patent/CN109476698B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201780044934.7A 2016-05-20 2017-05-19 基于基因的炎性肠病诊断 Active CN109476698B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311263442.0A CN117286238A (zh) 2016-05-20 2017-05-19 基于基因的炎性肠病诊断

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339357P 2016-05-20 2016-05-20
US62/339,357 2016-05-20
PCT/US2017/033625 WO2017201461A1 (en) 2016-05-20 2017-05-19 Diagnosis of inflammatory bowel disease based on genes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311263442.0A Division CN117286238A (zh) 2016-05-20 2017-05-19 基于基因的炎性肠病诊断

Publications (2)

Publication Number Publication Date
CN109476698A CN109476698A (zh) 2019-03-15
CN109476698B true CN109476698B (zh) 2023-10-17

Family

ID=60326226

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780044934.7A Active CN109476698B (zh) 2016-05-20 2017-05-19 基于基因的炎性肠病诊断
CN202311263442.0A Pending CN117286238A (zh) 2016-05-20 2017-05-19 基于基因的炎性肠病诊断

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311263442.0A Pending CN117286238A (zh) 2016-05-20 2017-05-19 基于基因的炎性肠病诊断

Country Status (6)

Country Link
US (2) US11549146B2 (https=)
EP (1) EP3458466B1 (https=)
JP (4) JP7475811B2 (https=)
KR (4) KR102481305B1 (https=)
CN (2) CN109476698B (https=)
WO (1) WO2017201461A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
KR102481305B1 (ko) * 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
CN116322762A (zh) * 2020-06-26 2023-06-23 辉瑞公司 用tl1a抗体治疗炎症性肠病的方法
CA3197828A1 (en) * 2020-11-13 2022-05-19 Laurens Kruidenier Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN115851911B (zh) * 2022-11-25 2025-10-24 南京鼓楼医院 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用
EP4646434A2 (en) * 2023-01-06 2025-11-12 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006768A1 (en) * 1998-07-25 2000-02-10 Astrazeneca Ab Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
CN1890384A (zh) * 2003-10-06 2007-01-03 诺瓦提斯公司 与炎性疾病的治疗功效相关的遗传多态性的用途
WO2007073478A2 (en) * 2005-12-19 2007-06-28 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
CN101688239A (zh) * 2007-02-12 2010-03-31 约翰·霍普金斯大学 结肠癌的早期检测和预后
WO2010062960A2 (en) * 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2011088380A1 (en) * 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using fut2 genetic variants to diagnose crohn's disease
US20110217310A1 (en) * 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2011153501A2 (en) * 2010-06-04 2011-12-08 Prometheus Laboratories Inc. Methods for improving inflammatory bowel disease diagnosis
WO2014186750A2 (en) * 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
CN104204230A (zh) * 2012-02-10 2014-12-10 诺和诺德A/S（股份有限公司） 治疗炎性疾病和病症的相关方法
WO2015054529A1 (en) * 2013-10-09 2015-04-16 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
CN104805198A (zh) * 2008-08-12 2015-07-29 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
HK1200933A1 (zh) * 2011-10-21 2015-08-14 Nestec S.A. 改善炎性肠病诊断的方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443421A (en) 1982-03-16 1984-04-17 Occidental Chemical Corporation Process for removing particulate impurities from aqueous phosphoric acid
DE3475880D1 (en) 1984-08-27 1989-02-09 Toray Industries Solid-liquid separating apparatus
US5000850A (en) 1986-09-10 1991-03-19 Engelhard Corporation Apparatus for dewatering an aqueous clay suspension
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
JP2004194534A (ja) 2002-12-17 2004-07-15 Sumitomo Pharmaceut Co Ltd 炎症性腸疾患疾患マーカーおよびその利用
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
CN102321174B (zh) 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
US20100055700A1 (en) 2007-02-28 2010-03-04 Cedars-Sinai Medical Center Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
US20150376707A1 (en) * 2007-05-18 2015-12-31 Cedars-Sinai Medical Center Methods of diagnosing and treating inflammatory bowel disease
US8118175B2 (en) 2007-07-18 2012-02-21 Siemens Industry, Inc. Venting device for a disc filter
US20100240043A1 (en) * 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
RU2011111748A (ru) 2008-08-29 2012-10-10 Сентокор Орто Байотек Инк. (Us) Маркеты и способы анализа и лечения язвенного колита и сходных заболеваний с использованием панели из 20 генов
JP2010088432A (ja) 2008-09-09 2010-04-22 Kansetsu Saisei Kenkyusho:Kk Ｔｎｆ阻害薬治療による有効性・副作用発現に関する多型、およびその利用
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
CA2758531C (en) 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
EP3260540A1 (en) 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
US9902996B2 (en) * 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
WO2012156515A1 (en) 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
KR20140104344A (ko) 2011-05-20 2014-08-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 Ｔ 세포 매개성 질병의 병증을 개선하기 위한 ｔｌ１ａ-ｄｒ３의 상호작용의 차단 및 그것의 항체
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
IL261228B2 (en) 2016-02-26 2023-12-01 Nanotech Energy Inc Methods, devices and systems for processing preparations containing carbon
KR102481305B1 (ko) 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
US11675142B2 (en) 2018-12-14 2023-06-13 Fujikura Ltd. Ferrule, fiber-equipped ferrule, and method for manufacturing fiber-equipped ferrule

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006768A1 (en) * 1998-07-25 2000-02-10 Astrazeneca Ab Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
CN1890384A (zh) * 2003-10-06 2007-01-03 诺瓦提斯公司 与炎性疾病的治疗功效相关的遗传多态性的用途
WO2007073478A2 (en) * 2005-12-19 2007-06-28 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
US20110217310A1 (en) * 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
CN101688239A (zh) * 2007-02-12 2010-03-31 约翰·霍普金斯大学 结肠癌的早期检测和预后
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
CN104805198A (zh) * 2008-08-12 2015-07-29 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
WO2010062960A2 (en) * 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2011088380A1 (en) * 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using fut2 genetic variants to diagnose crohn's disease
WO2011153501A2 (en) * 2010-06-04 2011-12-08 Prometheus Laboratories Inc. Methods for improving inflammatory bowel disease diagnosis
HK1200933A1 (zh) * 2011-10-21 2015-08-14 Nestec S.A. 改善炎性肠病诊断的方法
CN104204230A (zh) * 2012-02-10 2014-12-10 诺和诺德A/S（股份有限公司） 治疗炎性疾病和病症的相关方法
WO2014186750A2 (en) * 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
WO2015054529A1 (en) * 2013-10-09 2015-04-16 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HIDETOSHI TAKEDATSU等.TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating Both T-Helper 1 and T-Helper 17 Activation.《GASTROENTEROLOGY》.2008,第135卷552-567. *
Reversal of Murine Colitis and Fibrosis by Neutralizing TL1A Antibody: Potential Novel Therapy to Alter Natural History of Crohn"s Disease;David Q. Shih等;《Gastroenterology》;20120531;第142卷(第5期);S-84 *
rs918490;佚名;《dbSNP》;20080526;1-9 *
TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating Both T-Helper 1 and T-Helper 17 Activation;HIDETOSHI TAKEDATSU等;《GASTROENTEROLOGY》;20081231;第135卷;552-567 *
炎症性肠病的发病机制研究进展;周成会;刘纯伦;;重庆医学(第07期);861-864 *
遗传与环境因素在炎症性肠病发病机制中的作用研究;艾静等;《国际消化病杂志》;20140430;第34卷(第2期);110-113 *

Also Published As

Publication number Publication date
KR20220025122A (ko) 2022-03-03
US20190194754A1 (en) 2019-06-27
EP3458466B1 (en) 2024-08-07
KR20240095363A (ko) 2024-06-25
JP2024037945A (ja) 2024-03-19
JP7392020B2 (ja) 2023-12-05
KR102481305B1 (ko) 2022-12-26
JP2026048696A (ja) 2026-03-17
EP3458466A4 (en) 2020-03-04
KR20190016972A (ko) 2019-02-19
JP7475811B2 (ja) 2024-04-30
CN117286238A (zh) 2023-12-26
KR20230003433A (ko) 2023-01-05
US11549146B2 (en) 2023-01-10
JP2022095688A (ja) 2022-06-28
US20230366028A1 (en) 2023-11-16
JP2019516375A (ja) 2019-06-20
WO2017201461A1 (en) 2017-11-23
CN109476698A (zh) 2019-03-15
US12545959B2 (en) 2026-02-10
EP3458466A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
CN109476698B (zh) 基于基因的炎性肠病诊断
KR101708544B1 (ko) 세포 증식 질환을 분석하기 위한 방법 및 핵산
KR102046668B1 (ko) 암 대상자의 예후를 결정하기 위한 방법 및 핵산
CA3119065A1 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
CA2941594A1 (en) Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
CN107223159A (zh) 源自特定细胞类型的dna的检测及相关方法
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
KR20170086027A (ko) 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
CA2497597A1 (en) Methods for identifying subjects at risk of melanoma and treatments
AU2023203393A1 (en) Compositions and methods for screening and identifying clinically aggressive prostate cancer
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
EP1729930A2 (en) Methods for identifying risk of osteoarthritis and treatments thereof
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2006022634A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders
WO2006022638A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2018209358A2 (en) Systemic delivery of polypeptides
US20030124536A1 (en) Diagnosis and treatment of vascular disease
US20030219787A1 (en) Novel human gene functionally related to dyslexia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant